Based in Atlanta, Christian Fletcher guides LifeBrite Laboratories, an accredited medical laboratory with an array of services spanning chemistry testing, toxicology, and molecular pathology. In the latter area, Christian Fletcher and his team are pursuing a diagnostic testing vision of personalized patient care and precision medicine.
As described in Scientific American, new technologies are enabling physicians to detect and quantify a wide range of biomarkers that signal a disorder is present. They can then categorize patients within subgroups that reflect prognosis, disease susceptibility, and the likelihood of response to specific treatments. Therapies are designed, prescribed, and implemented based on subgroup genetic makeup, in ways that reduce adverse effect risks such as toxicity and improve outcomes.
With the FDA using the term “companion diagnostics” to describe this link between personalized medicine and pharmacogenomics, new drugs are also being developed to target people with specific genotypes and genetic mutations. LifeBrite Laboratories is at the diagnostic forefront of such genetic variability approaches through its molecular pathology capacities that encompass carrier testing, inherited cancer screening, microbiome analysis, and pharmacogenomics.
